Glenn J. Hanna
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Glenn J. Hanna sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
Glenn J. Hanna: 7 sponsored US clinical trials, 5 recruiting.
Glenn J. Hanna sponsors 7 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Adenoid Cystic Carcinoma, with 3 trials.
Upper-quartile sponsor footprint
Glenn J. Hanna sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
7 total, page 1 of 1
Toripalimab With Chemotherapy for Sinus Cancer
NCT06940180
A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers
NCT06805617
Phase II Study of RP2 as Immunoprevention in High-Risk Oral Precancerous Disease
NCT06623110
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
NCT06239220
CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC
NCT05774899
9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma
NCT05010629
Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC
NCT05057247
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 6 |
Therapeutic Areas
What is open in the Glenn J. Hanna pipeline
5 recruiting of 7 indexed (71% open); 1 completed (14%).
Phase mix: 0 late (III/IV) vs 7 early (I/II) (early-phase heavy).
Top condition: Adenoid Cystic Carcinoma (3 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Glenn J. Hanna: open-pipeline peers nationwide
Peers matched on 7 registered trials and 71% open enrollment, not the therapeutic-area sidebar.
Glenn J. Hanna sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 trials (± recruiting share)
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors near 71% open enrollment (± trial volume)
- Anna Stanhewicz, PhD · 71% recruiting · 14 trials
- Senthil Sadhasivam · 71% recruiting · 7 trials
- CorEvitas · 69% recruiting · 13 trials
- Revolution Medicines · 69% recruiting · 16 trials
Related
What to do with this Glenn J. Hanna page
7 registered trials is a research-attention snapshot, not an endorsement of Glenn J. Hanna or any single study.
- 5 of Glenn J. Hanna's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Adenoid Cystic Carcinoma is the condition Glenn J. Hanna studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Adenoid Cystic Carcinoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Glenn J. Hanna pipeline card: 7 registered trials from official public datasets.Report a data error.